Entirely Subcutaneous Defibrillator and Complex Congenital Heart Disease: Data on Long-term Clinical Follow-up

Overview

Journal World J Cardiol

Publisher Baishideng Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2017 Jul 15

PMID 28706590

Citations 3

Authors

Paolo Ferrero

Hussam Ali

Palash Barman

Sara Foresti

Pierpaolo Lupo

Emilia DElia

Riccardo Cappato

Alan Graham Stuart

Affiliations

Soon will be listed here.

Abstract

Aim: To describe the long-term follow-up of patients with complex congenital heart disease who underwent subcutaneous implantable cardiac defibrillator (S-ICD), focusing on local complications, appropriate and inappropriate shocks.

Methods: Patients with complex congenital heart disease underwent S-ICD implant in two centers with the conventional technique. Data at follow-up were retrieved from clinical notes and institutional database.

Results: Eight patients were implanted in two centres between 2010 and 2016. Median age at implant was 37.5 years (range 13-57). All patients who were deemed suitable for S-ICD implant passed the pre-procedural screening. Three patients were previously implanted with a anti-bradycardia device, one of whom with CRT. In one patient the device was explanted due to local infection. During the total median follow-up of 874 d, one patient had an appropriate and one inappropriate shock triggered by fast atrial tachycardia. None of the patients had inappropriate shocks secondary to T wave oversensing or electrical interference with anti- bradycardia devices.

Conclusion: S-ICD appears to be effective and safe in patients with complex congenital heart disease.

Citing Articles

Pre-implant screening guided by cardiac silhouette fluoroscopy: a way to increase eligibility for the subcutaneous implantable cardioverter-defibrillator: a case report.

Brito V, Bibiloni Cladera A, Exposito Pineda M, Grande Morales C Eur Heart J Case Rep. 2021; 5(1):ytaa495.

PMID: 33554026 PMC: 7850627. DOI: 10.1093/ehjcr/ytaa495.

Implantable Cardioverter-defibrillators in Adult Congenital Heart Disease.

Stewart M, Macicek S, Morin D J Innov Card Rhythm Manag. 2020; 9(6):3172-3181.

PMID: 32494493 PMC: 7252815. DOI: 10.19102/icrm.2018.090601.

European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society....

Blomstrom-Lundqvist C, Traykov V, Erba P, Burri H, Nielsen J, Bongiorni M Europace. 2019; 22(4):515-549.

PMID: 31702000 PMC: 7132545. DOI: 10.1093/europace/euz246.

References

Wilson D, Zeb M, Veldtman G, Dimitrov B, Morgan J . Left and Right Parasternal Sensing for the S-ICD in Adult Congenital Heart Disease Patients and Normal Controls. Pacing Clin Electrophysiol. 2015; 39(3):282-90. DOI: 10.1111/pace.12802. View

Bordachar P, Marquie C, Pospiech T, Pasquie J, Jalal Z, Haissaguerre M . Subcutaneous implantable cardioverter defibrillators in children, young adults and patients with congenital heart disease. Int J Cardiol. 2015; 203:251-8. DOI: 10.1016/j.ijcard.2015.09.083. View

Bouchardy J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Bottega N . Atrial arrhythmias in adults with congenital heart disease. Circulation. 2009; 120(17):1679-86. DOI: 10.1161/CIRCULATIONAHA.109.866319. View

Borleffs C, van Erven L, van Bommel R, van der Velde E, van der Wall E, Bax J . Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm Electrophysiol. 2009; 2(4):411-6. DOI: 10.1161/CIRCEP.108.834093. View

Okamura H, McLeod C, DeSimone C, Webster T, Bonnichsen C, Grogan M . Right Parasternal Lead Placement Increases Eligibility for Subcutaneous Implantable Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease. Circ J. 2016; 80(6):1328-35. DOI: 10.1253/circj.CJ-16-0153. View

Walsh E . Practical aspects of implantable defibrillator therapy in patients with congenital heart disease. Pacing Clin Electrophysiol. 2008; 31 Suppl 1:S38-40. DOI: 10.1111/j.1540-8159.2008.00954.x. View

Oechslin E, Harrison D, Connelly M, Webb G, Siu S . Mode of death in adults with congenital heart disease. Am J Cardiol. 2000; 86(10):1111-6. DOI: 10.1016/s0002-9149(00)01169-3. View

Gatzoulis M, Balaji S, Webber S, Siu S, Hokanson J, Poile C . Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000; 356(9234):975-81. DOI: 10.1016/S0140-6736(00)02714-8. View

Khairy P, Van Hare G, Balaji S, Berul C, Cecchin F, Cohen M . PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society.... Heart Rhythm. 2014; 11(10):e102-65. DOI: 10.1016/j.hrthm.2014.05.009. View

10.

Knops R, Brouwer T, Barr C, Theuns D, Boersma L, Weiss R . The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace. 2015; 18(7):1010-5. PMC: 4927061. DOI: 10.1093/europace/euv299. View

11.

Gold M, Theuns D, Knight B, Sturdivant J, Sanghera R, Ellenbogen K . Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2011; 23(4):359-66. DOI: 10.1111/j.1540-8167.2011.02199.x. View

12.

Germano J, Reynolds M, Essebag V, Josephson M . Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?. Am J Cardiol. 2006; 97(8):1255-61. DOI: 10.1016/j.amjcard.2005.11.048. View

13.

Groh C, Sharma S, Pelchovitz D, Bhave P, Rhyner J, Verma N . Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014; 11(8):1361-6. DOI: 10.1016/j.hrthm.2014.04.025. View

14.

Ali H, Lupo P, Cappato R . The Entirely Subcutaneous Defibrillator - A New Generation and Future Expectations. Arrhythm Electrophysiol Rev. 2016; 4(2):116-21. PMC: 4711556. DOI: 10.15420/aer.2015.04.02.116. View

15.

Griksaitis M, Rosengarten J, Gnanapragasam J, Haw M, Morgan J . Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation. Europace. 2013; 15(4):523-30. DOI: 10.1093/europace/eus388. View

16.

Silka M, Hardy B, MENASHE V, Morris C . A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998; 32(1):245-51. DOI: 10.1016/s0735-1097(98)00187-9. View

17.

Fortescue E, Berul C, Cecchin F, Walsh E, Triedman J, Alexander M . Patient, procedural, and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm. 2005; 1(2):150-9. DOI: 10.1016/j.hrthm.2004.02.020. View

18.

Bardy G, Smith W, Hood M, Crozier I, Melton I, Jordaens L . An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010; 363(1):36-44. DOI: 10.1056/NEJMoa0909545. View

19.

Hong P, Callinan P, Amit G, Healey J . Successful Implant of a Subcutaneous ICD System in a Patient with an Ipsilateral Epicardial Pacemaker. Indian Pacing Electrophysiol J. 2015; 15(1):62-4. PMC: 4380696. DOI: 10.1016/s0972-6292(16)30843-9. View